Aurobindo Pharma Share Price Falls 0.62% After USFDA Issues Four Observations at Lannett Company LLC in Seymour, Indiana on August 17-21, 2026

What Is the Aurobindo Pharma USFDA Inspection?

Aurobindo disclosed on August 24, 2026, that the US FDA inspected Lannett Company LLC, its wholly owned step-down subsidiary in Seymour, Indiana, from August 17 to 21, 2026. The inspection concluded with four observations. The company stated: "The inspection concluded with four observations, which are procedural in nature, and we will respond to the US FDA within the stipulated timeline."

Parameter	Detail
Entity Inspected	Lannett Company LLC, Seymour, Indiana, USA
Relationship to Aurobindo	Wholly owned step-down subsidiary
Inspection Dates	August 17 to 21, 2026
Number of Observations	Four
Nature of Observations	Procedural (per company disclosure)
Company Response	Will respond within stipulated timeline

Click Here – Get Free Investment Predictions

What Do FDA Observations Mean and How Serious Are Procedural Ones?

USFDA Form 483 observations range from minor procedural issues to critical data integrity failures. Aurobindo characterised the four observations at Lannett as procedural in nature, which suggests they relate to documentation or administrative compliance rather than critical quality or safety failures. Procedural observations are common across the pharmaceutical industry and are frequently resolved through updated procedures and training.

If the FDA determines the company's response is inadequate, it may escalate to a Warning Letter, which is a more serious action. Investors should monitor any follow-up USFDA communication. No Warning Letter has been disclosed for this inspection.

Screen Aurobindo Pharma on Univest Screener

Aurobindo Pharma Share Price Context

Aurobindo Pharma share price was trading at Rs 1,611.20 on August 24, 2026, down 0.62%. The Nifty Pharma index is the broader sector reference. The modest 0.62% decline reflects the market's reading of the situation as procedural rather than critical. If Aurobindo's response to the FDA is robust and the observations are resolved without escalation, the stock could recover toward prior levels.

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma share price and USFDA updates live.

Frequently Asked Questions

Why is Aurobindo Pharma share price down today?

Ans. Aurobindo Pharma share price fell 0.62% to Rs 1,611.20 on August 24, 2026, after the US FDA issued four observations following a routine inspection at Lannett Company LLC in Seymour, Indiana. The company has stated the observations are procedural in nature.

What are the four USFDA observations received by Aurobindo?

Ans. The US FDA inspected Lannett Company LLC from August 17 to 21, 2026, and issued four observations. Aurobindo described these as procedural in nature. The company will respond to the FDA within the stipulated timeline.

What is Lannett Company LLC and how is it related to Aurobindo Pharma?

Ans. Lannett Company LLC is a wholly owned step-down subsidiary of Aurobindo Pharma located in Seymour, Indiana, USA. It is part of Aurobindo's US generics manufacturing and distribution network.

What is Aurobindo Pharma share price today on August 24, 2026?

Ans. Aurobindo Pharma was trading at Rs 1,611.20 on August 24, 2026, down Rs 10.10 or 0.62% from the previous close of Rs 1,621.30.

Are USFDA observations serious for Aurobindo Pharma?

Ans. Aurobindo has characterised the four observations as procedural in nature, which suggests a lower severity level. No Warning Letter has been disclosed. Investors should monitor follow-up FDA communications for any escalation.

Is the Aurobindo USFDA inspection a Warning Letter?

Ans. No. The inspection concluded with four observations, not a Warning Letter. A Warning Letter is a more serious regulatory escalation that has not been disclosed for this inspection.